• 作者：Emilio Martí ; n Mola^a ; ^{emartinmola.hulp@salud.madrid.org} ; Blanca Herná ; ndez^b ; Miriam Garcí ; a-Arias^a ; José ; Marí ; a Á ; lvaro-Gracia^c ; Alejandro Balsa^a ; Juan Gó ; mez Reino^d ; José ; L. Marenco de la Fuente^e ; Ví ; ctor Martí ; nez-Taboada^f ; José ; André ; s Romá ; n Ivorra^g ; Raimon Sanmartí ; ^h ; el grupo de Expertos en Rituximab^&loz ;
• 关键词：Artritis reumatoide ; Rituximab ; Terapias bioló ; gicas ; Consenso
• 刊名：Reumatolog铆a Cl铆nica
• 出版年：2011
• 期刊代码：pca303_1699258X
• 类别：med
• 出版时间：January-February 2011
• 卷：7
• 期：1
• 页码：30-44
• 文件大小：258 K

Introduction

Rituximab has been employed successfully for the treatment of Rheumatoid Arthritis (RA). However, its particular mechanism of action, as well as a lack of concrete guidelines for its management have generated doubts on its use.

Objective

To establish recommendations that facilitates the use of rituximab in common clinical practice.

Methods

In a first Delphi round, 9 expert rheumatologists got together to develop questions on those subjects generating most doubts on the efficacy and safety of the drug. These were adapted to perform a systematic review of the evidence, which was presented in a second meeting. Nominal groups were formed to respond to each question and give a recommendation. These recommendations were presented in a second Delphi round to a larger group of experts in rheumatology. Once again recommendations were discussed, modified and voted upon. Once approved, a vote on the degree of agreement for each recommendation was carried out.

Results

17 recommendations were established, 10 regarding efficacy and 7 safety. All of the efficacy recommendations except 3 presented a good or moderate degree of evidence. Among the safety recommendations, 3 had a good or moderate degree of evidence while in the rest it was indirect, scarce or non-existent and a product of expert recommendation. The degree of agreement between experts was elevated for most of the recommendations.

Conclusions

These recommendations attempt to clear doubts on the use of rituximab and establish guidelines for its use in daily practice. Efficacy recommendations have a high degree of evidence, allowing the clinician to be guided in therapeutic decisions. Safety recommendations have a lower degree of evidence.